Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City

  Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw
     Global Investment Conference In New York City September 8-10th, 2013

PR Newswire

TARRYTOWN, N.Y., Sept. 4, 2013

TARRYTOWN, N.Y., Sept. 4, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc.
(NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will
be featured as a presenting company at the 15^th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The
conference is being heldSeptember 8-10, 2013, at the Millennium Broadway
Hotel in New York City.

Daniel Teper, CEO of Immune Pharmaceuticals Inc., will provide an overview of
the Company's business during the live presentation and will be available to
participate in one-on-one meetings with investors who are registered to attend
the conference.

If you are an institutional investor, and would like to attend the Company's
presentation, please click on the following link (www.rodm.com) to register
for the Rodman & Renshaw conference. Once your registration is confirmed, you
will be prompted to log into the conference website to request a one-on-one
meeting with the Company.

Follow the official Rodman & Renshaw handle on Twitter @Rodman_2013 and use
#Rodman2013 for conference information and updates. 

Event: 15^th Annual Rodman & Renshaw Global Investment Conference
Date: Monday, September 9, 2013
Time: 4:05 PM (Eastern Time)
Location: Room 7.01, 7th Floor, Millennium Broadway Hotel in New York City

The presentation will be accessible within a few days and for the next 90 days
at www.immunepharmaceuticals.com.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP; OTCQX:
EPCTD,) applies a personalized approach to treatment, developing novel, highly
targeted antibody therapeutics to improve the lives of patients with
inflammatory diseases and cancer. The Company's lead product candidate,
bertilimumab, is entering Phase II clinical studies for moderate-to-severe
ulcerative colitis and bullous pemphigoid, with additional studies planned for
Crohn's disease and severe asthma. The Company is evaluating the use of its
NanomAb® platform, a second generation antibody drug conjugate technology,
with chemotherapeutics in order to enhance their safety and efficacy profiles
by delivering the medicines directly to cancer cells. The Company's growing
oncology pipeline also includes proprietary antibodies and, clinical-stage
small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in the U.S., with its primary research and development
facilities in Israel.

For more information, visit Immune's website at www.immunepharmaceuticals.com.

Forward-Looking Statements

This news release and any oral statements made with respect to the information
contained in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. You are
urged to consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal" or the negative of those words or other comparable words to
be uncertain and forward-looking. Such forward-looking statements include
statements that express plans, anticipation, intent, contingency, goals,
targets, future development and are otherwise not statements of historical
fact. These statements are based on our current expectations and are subject
to risks and uncertainties that could cause actual results or developments to
be materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Factors that may
cause actual results or developments to differ materially include: the risks
associated with the adequacy of our existing cash resources and our ability to
continue as a going concern; the risks associated with our ability to continue
to meet our obligations under our existing debt agreements; the risk that
clinical trials for bertilimumab, crolibulin or AmiKet™ will not be
successful; the risk that bertilimumab, crolibulin, AmiKet™ or compounds
arising from our NanomAb® program will not receive regulatory approval or
achieve significant commercial success; the risk that we will not be able to
find a partner to help conduct the Phase III trials for AmiKet™ on attractive
terms, a timely basis or at all; the risk that our other product candidates
that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later-stage clinical
trials; the risk that we will not obtain approval to market any of our product
candidates; the risks associated with dependence upon key personnel; the risks
associated with reliance on collaborative partners and others for further
clinical trials, development, manufacturing and commercialization of our
product candidates; the cost, delays and uncertainties associated with our
scientific research, product development, clinical trials and regulatory
approval process; our history of operating losses since our inception; the
highly competitive nature of our business; risks associated with litigation;
and risks associated with our ability to protect our intellectual property.
These factors and other material risks are more fully discussed in our
periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other
filings with the U.S. Securities and Exchange Commission. You are urged to
carefully review and consider the disclosures found in our filings which are
available at www.sec.gov or at www.immunepharmaceuticals.com. You are
cautioned not to place undue reliance on any forward-looking statements, any
of which could turn out to be wrong due to inaccurate assumptions, unknown
risks or uncertainties or other risk factors.

EPCTD-GEN

SOURCE Immune Pharmaceuticals Inc.

Website: http://www.immunepharmaceuticals.com
Contact: Immune Pharmaceuticals Inc.: 777 Old Saw Mill River Road, Tarrytown,
NY 10591, Anna Baran, Director of Investor Relations and Corporate
Communications, Tel: (914) 606-3500 or (646) 937-1941,
anna.baran@immunepharma.com; or Immune Pharmaceuticals Ltd.: 15 Aba Even
Avenue, 2nd Floor, Herzliya-Pituach, 46733, Israel